Bicycle Therapeutics (NASDAQ:BCYC) Rating Increased to Hold at Wall Street Zen

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also issued reports on BCYC. Citizens Jmp dropped their target price on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Needham & Company LLC reduced their price target on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial set a $8.00 price objective on shares of Bicycle Therapeutics in a report on Tuesday. Finally, Royal Bank Of Canada cut their price objective on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Hold” and an average target price of $14.50.

Bicycle Therapeutics Stock Down 4.4%

Shares of NASDAQ:BCYC opened at $4.35 on Friday. The company has a market cap of $301.75 million, a price-to-earnings ratio of -1.38 and a beta of 1.65. The business has a 50 day moving average price of $5.78 and a 200 day moving average price of $6.76. Bicycle Therapeutics has a twelve month low of $4.30 and a twelve month high of $9.69.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.71. Bicycle Therapeutics had a negative return on equity of 33.21% and a negative net margin of 301.66%.The company had revenue of $47.96 million for the quarter, compared to the consensus estimate of $7.08 million. Analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $70,988.94. Following the sale, the chief executive officer owned 618,996 shares in the company, valued at $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Alethia Young sold 4,334 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the completion of the sale, the chief financial officer directly owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 38,029 shares of company stock valued at $251,966. 22.90% of the stock is owned by company insiders.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCYC. Principal Financial Group Inc. lifted its stake in Bicycle Therapeutics by 64.7% during the third quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock worth $8,889,000 after purchasing an additional 451,135 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $320,000. Jefferies Financial Group Inc. lifted its position in shares of Bicycle Therapeutics by 12.8% during the 2nd quarter. Jefferies Financial Group Inc. now owns 461,100 shares of the company’s stock worth $3,205,000 after buying an additional 52,211 shares during the period. Long Focus Capital Management LLC boosted its stake in Bicycle Therapeutics by 7.7% in the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after buying an additional 101,402 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in Bicycle Therapeutics by 4.8% in the 2nd quarter. Armistice Capital LLC now owns 2,800,000 shares of the company’s stock valued at $19,460,000 after buying an additional 128,000 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.